Key Points
- Insider selling: Gwenn Hansen sold 4,111 Nurix shares for approximately $100,144 under a pre-arranged Rule 10b5-1 plan, reducing her holdings by 3.39% to 117,227 shares. She also made several recent sales, including 8,467 shares across August 4–5.
- Pipeline progress: Nurix is set to receive a $10 million milestone payment from Sanofi after initiation of a Phase 1 trial for a STAT6 degrader, and enrolled the first patient in its registrational Phase 3 trial of bexobrutideg for relapsed or refractory CLL/SLL.
- Analyst outlook remains positive: Thirteen analysts rate NRIX a Buy, with a consensus “Moderate Buy” rating and a $34 price target versus the referenced share price near $25.12. However, the company recently missed quarterly earnings and revenue estimates and continues to report substantial losses.
Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) insider Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $100,143.96. Following the transaction, the insider directly owned 117,227 shares in the company, valued at approximately $2,855,649.72. This represents a 3.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Gwenn Hansen also recently made the following trade(s):
- On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total value of $108,900.00.
- On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total value of $89,942.86.
- On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $107,880.00.
Nurix Therapeutics Trading Up 1.7%
Shares of Nurix Therapeutics stock opened at $25.12 on Thursday. The business's fifty day simple moving average is $20.95 and its 200 day simple moving average is $17.96. The firm has a market capitalization of $2.61 billion, a P/E ratio of -7.28 and a beta of 1.79. Nurix Therapeutics, Inc. has a 12 month low of $8.19 and a 12 month high of $25.40.
Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The business had revenue of $9.04 million during the quarter, compared to analysts' expectations of $15.29 million. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. Analysts predict that Nurix Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts have commented on NRIX shares. Royal Bank Of Canada lifted their price objective on shares of Nurix Therapeutics from $30.00 to $33.00 and gave the stock an "outperform" rating in a research report on Friday, July 10th. Robert W. Baird increased their price objective on Nurix Therapeutics from $26.00 to $33.00 and gave the company an "outperform" rating in a report on Thursday, June 18th. Truist Financial raised their target price on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $34.00 price target on shares of Nurix Therapeutics in a research report on Tuesday. Finally, Jefferies Financial Group increased their price target on Nurix Therapeutics from $41.00 to $45.00 and gave the stock a "buy" rating in a research note on Monday, June 8th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Nurix Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $34.00.
View Our Latest Research Report on Nurix Therapeutics
Key Stories Impacting Nurix Therapeutics
Here are the key news stories impacting Nurix Therapeutics this week:
- Positive Sentiment: Nurix will receive a $10 million milestone payment after Sanofi initiated a Phase 1 trial of the oral STAT6 degrader SAR448272/NX-3911 for type 2 inflammatory diseases. The company has earned approximately $139 million from the Sanofi collaboration and remains eligible for about $453 million in additional milestones, plus potential royalties and a U.S. co-development option. Nurix Announces $10 Million Milestone Payment
- Positive Sentiment: The company enrolled the first patient in the registrational Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The study is designed to test whether bexobrutideg can outperform pirtobrutinib, a key step toward potential regulatory approval and commercialization. Nurix Announces Phase 3 DAYBreak CLL-306 Enrollment
- Positive Sentiment: Needham reaffirmed its Buy rating and maintained a $34 price target, implying substantial upside from the referenced share price. The endorsement reflects continued analyst confidence in Nurix’s pipeline and commercial potential. Needham Rating Update
- Negative Sentiment: Insiders reported additional sales: CFO Hans van Houte sold 4,761 shares for approximately $116,000, while Gwenn Hansen sold 8,467 shares across August 4–5 for roughly $209,000. The transactions were conducted under pre-arranged Rule 10b5-1 plans, reducing their significance as a bearish signal, but they still represent some near-term insider selling pressure.
Institutional Investors Weigh In On Nurix Therapeutics
Institutional investors have recently made changes to their positions in the stock. General Atlantic L.P. bought a new position in shares of Nurix Therapeutics in the fourth quarter worth $92,899,000. Morgan Stanley grew its position in shares of Nurix Therapeutics by 115.9% in the fourth quarter. Morgan Stanley now owns 4,881,069 shares of the company's stock valued at $92,594,000 after purchasing an additional 2,620,323 shares in the last quarter. Rubric Capital Management LP bought a new stake in shares of Nurix Therapeutics during the 4th quarter valued at $46,930,000. Braidwell LP bought a new stake in shares of Nurix Therapeutics during the 4th quarter valued at $41,428,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Nurix Therapeutics by 195.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,248,361 shares of the company's stock valued at $61,622,000 after purchasing an additional 2,149,268 shares during the period.
Nurix Therapeutics Company Profile
(
Get Free Report)
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.
The company's pipeline includes multiple programs in various stages of development.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
